The departure plan at Sanofi is struggling to pass in France.
And the delay taken by the French laboratory in the race for anti-Covid vaccines gives grain to grind to its opponents.
Last June, the management of the company announced 1,700 job cuts in Europe over three years, including 1,000 in France, the country most affected.
Among the first concerned, the research and development (R&D) teams with 300 to 400 jobs in their sights.
These cuts were justified at the time by Sanofi's desire to
"strengthen the efficiency"
of its organization.
Read also:
Covid-19: Sanofi is studying the possibility of manufacturing the vaccines of competitors
While discussions with the social partners on R&D are about to start, the unions sounded the alarm bell in the media on Monday on these workforce reductions.
For the CGT, which calls on employees to go on strike Tuesday,
“Sanofi continues to lose skills.
See what's going on with the vaccine there too!
These losses, we pay them cash. "
These critiques have taken a turn
This article is for subscribers only.
You have 69% left to discover.
Subscribe: 1 € the first month
Can be canceled at any time
I ENJOY IT
Already subscribed?
Log in
